CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats
- PMID: 26607463
- DOI: 10.1016/j.ejphar.2015.11.028
CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats
Abstract
The present study was designed to evaluate the antihypertensive and cardiorenal protective effects of CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, in Dahl salt-sensitive hypertensive rats (DS rats), and to compare the effects with spironolactone and eplerenone. DS rats were fed a control diet (0.3% NaCl) or high salt diet (8% NaCl) from 7 weeks of age. CS-3150 (0.25-2mg/kg), spironolactone (10-100mg/kg) or eplerenone (10-100mg/kg) were orally administered once a day to DS rats fed a high salt diet for 7 weeks. The high salt diet significantly increased systolic blood pressure, which was prevented by treatment with CS-3150 in a dose-dependent manner with no hyperkalemia (>5.5mEq/L). The antihypertensive effect of CS-3150 (0.5mg/kg) was equivalent to that of spironolactone (100mg/kg) and eplerenone (100mg/kg). CS-3150 also suppressed proteinuria and renal hypertrophy induced by the high salt diet. Histopathological examination of kidneys showed that CS-3150 markedly ameliorated glomerulosclerosis, tubular injury and tubulointerstitial fibrosis. In addition, CS-3150 inhibited left ventricular hypertrophy and elevation of plasma brain natriuretic peptide level. In contrast, the cardiorenal protective effects of spironolactone or eplerenone were partial, and the dose-dependency was not clear, especially in eplerenone-treated rats. These results indicate that chronic treatment with CS-3150 exerts antihypertensive and cardiorenal protective effects in a DS hypertensive rat model, and its potency is much superior to that of spironolactone or eplerenone. Thus, CS-3150 could be a promising agent for the treatment of hypertension and cardiorenal disorders.
Keywords: Aldosterone; CS-3150; Mineralocorticoid receptor antagonist; Renal injury; Salt-sensitive hypertension.
Copyright © 2015 Elsevier B.V. All rights reserved.
Similar articles
-
CS-3150, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, Shows Preventive and Therapeutic Effects On Renal Injury in Deoxycorticosterone Acetate/Salt-Induced Hypertensive Rats.J Pharmacol Exp Ther. 2016 Sep;358(3):548-57. doi: 10.1124/jpet.116.234765. Epub 2016 Jul 6. J Pharmacol Exp Ther. 2016. PMID: 27384074
-
Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.Int J Cardiol. 2015 Dec 1;200:25-9. doi: 10.1016/j.ijcard.2015.05.127. Epub 2015 May 21. Int J Cardiol. 2015. PMID: 26404748 Review.
-
Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.Eur J Pharmacol. 2015 Aug 15;761:226-34. doi: 10.1016/j.ejphar.2015.06.015. Epub 2015 Jun 11. Eur J Pharmacol. 2015. PMID: 26073023
-
Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats.Am J Physiol Renal Physiol. 2009 Sep;297(3):F802-8. doi: 10.1152/ajprenal.00197.2009. Epub 2009 Jun 17. Am J Physiol Renal Physiol. 2009. PMID: 19535572
-
Effects of eplerenone, a selective mineralocorticoid receptor antagonist, on clinical and experimental salt-sensitive hypertension.Hypertens Res. 2009 May;32(5):321-4. doi: 10.1038/hr.2009.29. Epub 2009 Mar 20. Hypertens Res. 2009. PMID: 19300447 Review.
Cited by
-
Esaxerenone: blood pressure reduction and cardiorenal protection without reflex sympathetic activation in salt-loaded stroke-prone spontaneously hypertensive rats.Hypertens Res. 2024 May 27. doi: 10.1038/s41440-024-01733-4. Online ahead of print. Hypertens Res. 2024. PMID: 38802501
-
Huoxue Jiedu Huayu recipe inhibits macrophage-secreted vascular endothelial growth factor-a on angiogenesis and alleviates renal fibrosis in the contralateral kidneys of unilateral ureteral obstruction rats.J Tradit Chin Med. 2024 Jun;44(3):458-467. doi: 10.19852/j.cnki.jtcm.20240423.005. J Tradit Chin Med. 2024. PMID: 38767629 Free PMC article.
-
Efficacy and Safety of Esaxerenone in Hypertensive Patients with Left Ventricular Hypertrophy (ESES-LVH) Study: A Multicenter, Open-Label, Prospective, Interventional Study.Adv Ther. 2024 Mar;41(3):1284-1303. doi: 10.1007/s12325-024-02780-6. Epub 2024 Feb 4. Adv Ther. 2024. PMID: 38310194 Free PMC article. Clinical Trial.
-
Esaxerenone Protects against Diabetic Cardiomyopathy via Inhibition of the Chemokine and PI3K-Akt Signaling Pathway.Biomedicines. 2023 Dec 15;11(12):3319. doi: 10.3390/biomedicines11123319. Biomedicines. 2023. PMID: 38137541 Free PMC article.
-
Cardiovascular and Renal Benefit of Novel Non-steroidal Mineralocorticoid Antagonists in Patients with Diabetes.Curr Cardiol Rep. 2023 Dec;25(12):1859-1864. doi: 10.1007/s11886-023-01998-0. Epub 2023 Nov 22. Curr Cardiol Rep. 2023. PMID: 37991625 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical